Paisey R B, Kadow C, Bolton C, Hartog M, Gingell J C
J R Soc Med. 1986 Apr;79(4):210-1. doi: 10.1177/014107688607900407.
Fasting serum lipoproteins were measured in 10 untreated patients with carcinoma of the prostate (Group I), 17 patients with non-malignant urological disorders (Group II), and 12 patients on cyproterone acetate (Group III) and 5 on a long-acting luteinizing hormone-releasing hormone (LHRH) analogue (Group IV) for at least 2 months for carcinoma of the prostate. Total high-density lipoprotein (HDL) cholesterol levels were significantly lower in patients in Group III than all the other groups. Very low-density lipoprotein (VLDL) triglyceride levels were significantly higher in patients in Group III than those in Groups II and IV. These results suggest a potentially adverse effect of cyproterone acetate, but not of the long-acting LHRH analogue, on serum lipids, which is likely to be of relevance only in younger patients.
对10例未经治疗的前列腺癌患者（第一组）、17例患有非恶性泌尿系统疾病的患者（第二组）、12例接受醋酸环丙孕酮治疗的患者（第三组）以及5例接受长效促黄体生成激素释放激素（LHRH）类似物治疗至少2个月的前列腺癌患者（第四组）测定了空腹血清脂蛋白。第三组患者的总高密度脂蛋白（HDL）胆固醇水平显著低于所有其他组。第三组患者的极低密度脂蛋白（VLDL）甘油三酯水平显著高于第二组和第四组患者。这些结果表明，醋酸环丙孕酮对血脂有潜在的不良影响，但长效LHRH类似物没有，这种影响可能仅在年轻患者中具有相关性。
